期刊文献+

虚拟现实与医学交互及前景 被引量:13

Interaction and Prospect of Virtual Reality and Medicine
下载PDF
导出
摘要 2016年作为VR元年,虚拟现实产业得到了Facebook、索尼、谷歌等多方融资并初步确定了其在教育、军事及医学上的发展前景。今年虚拟现实技术在沉浸感、交互性等方面均有突破。医学与虚拟现实交互作为重点发展领域之一,表现的尤为突出,所开发出来的虚拟课堂和虚拟手术不仅对已经熟练掌握手术技术的老医师有着辅助手术完成的更精准更成功的能力,还加快了对新医师的培养,在缩短了新医师掌握并熟练运用医学知识及技巧的时间的同时,降低了在医师培训上的花销。医生一直以来是全世界最难的职业之一,其难实践、难训练的特点尤为突出,导致新医师成长过慢且难入行,虚拟现实便完美解决了这一难题。在药物开发方面,建立药物分子模型、测试药物性能、改进药物性能可以让更高效的新药快速研发。在术后康复方面也作为代替止痛药功能的"良药"活跃在世界最顶尖的医院。在治疗癌症等绝症的方面也有着不小的辅助作用。 In the year of 2016, as the original year of virtual reality, the technology gets many equity tradings from Facebook, Sony, Google, etc. They make sure the developing field of VR such as education, military and medical science. Today VR makes a breakthrough in aspect of immersion and reciprocity. As an important field of VR, medical science has a great representation. The virtual class and virtual operation not only help the old doctors complete the opertion more accurately and successfully, but also train young doctors for profession faster. It can help the young doctors know well and be skilled in using medical knowledge and technique faster and cut the training cost. Doctor is always one of the most difficult occupations in the world. The reason is its outstanding feature: few and difficult practice. It causes difficult for people to become a doctor. The VR sovles the problem faultlessly. In aspect of researching new medicine, building a medical numerator model, testing the performance of medicine, improving its function, VR makes them faster. In the aspect of postoperative rehabilitation, VR can replace the acesodyne. In the aspect of treating cancer, it also has effects.
作者 曹红
出处 《中国继续医学教育》 2017年第28期9-10,共2页 China Continuing Medical Education
关键词 虚拟现实技术 医学教学研究 新药研发 virtual reality study on medical teaching research of medicine
  • 相关文献

参考文献3

二级参考文献64

  • 1王瑞利,刘更谦,于庆增,张小俊.基于虚拟现实踝关节康复系统的研究[J].机电产品开发与创新,2007,20(1):16-17. 被引量:10
  • 2程德文,王涌天,常军,刘越,徐况.轻型大视场自由曲面棱镜头盔显示器的设计[J].红外与激光工程,2007,36(3):309-311. 被引量:24
  • 3O'Brien SG,Guilhot F,Larson RA,et al.Imatinib com- pared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J].N Engl J Med, 2003,348 (11) : 994-1004.
  • 4Kantoff PW, Higano CS,Shore ND,et al.Sipuleucel-T im- munotherapy for castration-resistant prostate cancer[J].N Engl J Med, 2010,363(5) : 411-422.
  • 5Robert C ,Thomas L, Bondarenko I, et al, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma [J]. N Engl J Med, 2011,364(26): 2517-2526.
  • 6Rakhra K, Bachireddy P,Zabuawala T,et al. CD4+ T cells contrilmte to the remodeling of the microenvironment re- quired for sustained tumor regression upon oncogene inac- tivation[J].Cancer Cell, 2010,18(6) : 485-498.
  • 7Nefedova Y, Nagaraj S, Rosenbauer A, et al. Regulation of dendritic cell differentiation and antitumor immune re- sponse in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activa- tors of transcription 3 pathway[J]. Cancer Res, 2005,65(20): 9525-9535.
  • 8Seeger JM,Schmidt P,Brinkmann K,et al.The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack[J].Cancer Res,2010,70(5): 1825-1834.
  • 9Steinman RM,Mellman I. Immunotherapy:bewitehed,both- ered,and bewildered no more[J]. Science,2004,305(5681): 197-200.
  • 10Greenwald RJ,Freeman GJ,Sharpe AH.The B7 family re- visited[J].Annu Rev Immunol, 2005,23 : 515-548.

共引文献29

同被引文献153

引证文献13

二级引证文献90

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部